Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease characterized by a loss of tolerance to multiple endogenous antigens. SLE etiology remains largely unknown, despite recent insight into the immunopathogenesis of the disease. T cells are important in the development of the disease by amplifying the immune response and contributing to organ damage. Aberrant signaling, cytokine secretion, and tissue homing displayed by SLE T cells have been extensively studied and the underlying pathogenic molecular mechanisms are starting to be elucidated. T-cell-targeted treatments are being explored in SLE patients. This review is an update on the T-cell abnormalities and related therapeutic options in SLE.
TsokosGC. Systemic lupus erythematosus. N Engl J Med2011; 365: 2110–2121.
2.
ShlomchikMJCraftJEMamulaMJ. From T to B and back again: Positive feedback in systemic autoimmune disease. Nat Rev Immunol2001; 1: 147–153.
3.
ZhouYYuanJPanY. T cell CD40LG gene expression and the production of IgG by autologous B cells in systemic lupus erythematosus. Clin Immunol2009; 132: 362–370.
4.
EnyedyEJNambiarMPLiossisSNDennisGKammerGMTsokosGC. Fc epsilon receptor type I gamma chain replaces the deficient T cell receptor zeta chain in T cells of patients with systemic lupus erythematosus. Arthritis Rheum2001; 44: 1114–1121.
5.
KrishnanSJuangYTChowdhuryB. Differential expression and molecular associations of Syk in systemic lupus erythematosus T cells. J Immunol2008; 181: 8145–8152.
6.
LiossisSNDingXZDennisGJTsokosGC. Altered pattern of TCR/CD3-mediated protein-tyrosyl phosphorylation in T cells from patients with systemic lupus erythematosus. Deficient expression of the T cell receptor zeta chain. J Clin Invest1998; 101: 1448–1457.
7.
KyttarisVCWangYJuangYTWeinsteinATsokosGC. Increased levels of NF–ATc2 differentially regulate CD154 and IL-2 genes in T cells from patients with systemic lupus erythematosus. J Immunol2007; 178: 1960–1966.
DengGMLiuLBahjatFRPinePRTsokosGC. Suppression of skin and kidney disease by inhibition of spleen tyrosine kinase in lupus-prone mice. Arthritis Rheum2010; 62: 2086–2092.
10.
WeinblattMEKavanaughAGenoveseMCMusserTKGrossbardEBMagilavyDB. An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. N Engl J Med2010; 363: 1303–1312.
11.
GenoveseMCKavanaughAWeinblattME. An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: A three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents. Arthritis Rheum2011; 63: 337–345.
12.
PodolanczukALazarusAHCrowARGrossbardEBusselJB. Of mice and men: An open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk. Blood2009; 113: 3154–3160.
13.
Suárez-FueyoARojasJMCariagaAE. Inhibition of PI3Kdelta reduces kidney infiltration by macrophages and ameliorates systemic lupus in the mouse. J Immunol2014; 193: 544–554.
14.
BarberDFBartoloméAHernandezC. PI3Kgamma inhibition blocks glomerulonephritis and extends lifespan in a mouse model of systemic lupus. Nat Med2005; 11: 933–935.
15.
LiYHaradaTJuangYT. Phosphorylated ERM is responsible for increased T cell polarization, adhesion, and migration in patients with systemic lupus erythematosus. J Immunol2007; 178: 1938–1947.
16.
DengGMTsokosGC. Cholera toxin B accelerates disease progression in lupus-prone mice by promoting lipid raft aggregation. J Immunol2008; 181: 4019–4026.
17.
JuryECIsenbergDAMauriCEhrensteinMR. Atorvastatin restores Lck expression and lipid raft-associated signaling in T cells from patients with systemic lupus erythematosus. J Immunol2006; 177: 7416–7422.
18.
McDonaldGDeepakSMiguelL. Normalizing glycosphingolipids restores function in CD4+ T cells from lupus patients. J Clin Invest2014; 124: 712–724.
19.
CrispínJCKeenanBTFinnellMD. Expression of CD44 variant isoforms CD44v3 and CD44v6 is increased on T cells from patients with systemic lupus erythematosus and is correlated with disease activity. Arthritis Rheum2010; 62: 1431–1437.
20.
YungSChanTM. Pathophysiology of the peritoneal membrane during peritoneal dialysis: The role of hyaluronan. J Biomed Biotechnol2011; 2011: 180594–180594.
21.
CohenRABaylissGCrispínJC. T cells and in situ cryoglobulin deposition in the pathogenesis of lupus nephritis. Clin Immunol2008; 128: 1–7.
22.
BiswasPSGuptaSChangE. Phosphorylation of IRF4 by ROCK2 regulates IL-17 and IL-21 production and the development of autoimmunity in mice. J Clin Invest2010; 120: 3280–3295.
23.
AltmanATheofilopoulosANWeinerRKatzDHDixonFJ. Analysis of T cell function in autoimmune murine strains. Defects in production and responsiveness to interleukin 2. J Exp Med1981; 154: 791–808.
24.
Alcocer-VarelaJAlarcón-SegoviaD. Decreased production of and response to interleukin-2 by cultured lymphocytes from patients with systemic lupus erythematosus. J Clin Invest1982; 69: 1388–1392.
25.
Linker-IsraeliMBakkeACKitridouRCGendlerSGillisSHorwitzDA. Defective production of interleukin 1 and interleukin 2 in patients with systemic lupus erythematosus (SLE). J Immunol1983; 130: 2651–2655.
26.
LiaoWLinJXLeonardWJ. IL-2 family cytokines: New insights into the complex roles of IL-2 as a broad regulator of T helper cell differentiation. Curr Opin Immunol2011; 23: 598–604.
27.
PipkinMESacksJACruz-GuillotyFLichtenheldMGBevanMJRaoA. Interleukin-2 and inflammation induce distinct transcriptional programs that promote the differentiation of effector cytolytic T cells. Immunity2010; 32: 79–90.
28.
LenardoMJ. Interleukin-2 programs mouse alpha beta T lymphocytes for apoptosis. Nature1991; 353: 858–861.
29.
YuAZhuLAltmanNHMalekTR. A low interleukin-2 receptor signaling threshold supports the development and homeostasis of T regulatory cells. Immunity2009; 30: 204–217.
30.
MalekTRYuAVincekVScibelliPKongL. CD4 regulatory T cells prevent lethal autoimmunity in IL-2Rbeta-deficient mice. Implications for the nonredundant function of IL-2. Immunity2002; 17: 167–178.
31.
LaurenceATatoCMDavidsonTS. Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation. Immunity2007; 26: 371–381.
32.
Amadi-ObiAYuCRLiuX. TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27/STAT1. Nat Med2007; 13: 711–718.
33.
KlebbGAutenriethIBHaberH. Interleukin-2 is indispensable for development of immunological self-tolerance. Clin Immunol Immunopathol1996; 81: 282–286.
34.
MizuiMKogaTLiebermanLA. IL-2 Protects lupus-prone mice from multiple end-organ damage by limiting CD4–CD8– IL-17-producing T cells. J Immunol2014; 193: 2168–2177.
35.
KorethJMatsuokaKKimHT. Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med2011; 365: 2055–2066.
36.
SaadounDRosenzwajgMJolyF. Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. N Engl J Med2011; 365: 2067–2077.
37.
JainJLohCRaoA. Transcriptional regulation of the IL-2 gene. Curr Opin Immunol1995; 7: 333–342.
38.
KyttarisVCJuangYTTenbrockKWeinsteinATsokosGC. Cyclic adenosine 5'-monophosphate response element modulator is responsible for the decreased expression of c-fos and activator protein-1 binding in T cells from patients with systemic lupus erythematosus. J Immunol2004; 173: 3557–3563.
39.
WongHKKammerGMDennisGTsokosGC. Abnormal NF-kappa B activity in T lymphocytes from patients with systemic lupus erythematosus is associated with decreased p65-RelA protein expression. J Immunol1999; 163: 1682–1689.
40.
KatsiariCGKyttarisVCJuangYTTsokosGC. Protein phosphatase 2A is a negative regulator of IL-2 production in patients with systemic lupus erythematosus. J Clin Invest2005; 115: 3193–3204.
41.
SolomouEEJuangYTGourleyMFKammerGMTsokosGC. Molecular basis of deficient IL-2 production in T cells from patients with systemic lupus erythematosus. J Immunol2001; 166: 4216–4222.
42.
NambiarMPFisherCUWarkeVG. Reconstitution of deficient T cell receptor zeta chain restores T cell signaling and augments T cell receptor/CD3-induced interleukin-2 production in patients with systemic lupus erythematosus. Arthritis Rheum2003; 48: 1948–1955.
43.
JuangYTWangYSolomouEE. Systemic lupus erythematosus serum IgG increases CREM binding to the IL-2 promoter and suppresses IL-2 production through CaMKIV. J Clin Invest2005; 115: 996–1005.
44.
IchinoseKJuangYTCrispínJCKis-TothKTsokosGC. Suppression of autoimmunity and organ pathology in lupus-prone mice upon inhibition of calcium/calmodulin-dependent protein kinase type IV. Arthritis Rheum2011; 63: 523–529.
45.
KogaTMizuiMYoshidaN. KN-93, an inhibitor of calcium/calmodulin-dependent protein kinase IV, promotes generation and function of Foxp3 regulatory T cells in MRL/lpr mice. Autoimmunity2014, pp. 1–6.
46.
MoultonVRTsokosGC. Alternative splicing factor/splicing factor 2 regulates the expression of the zeta subunit of the human T cell receptor-associated CD3 complex. J Biol Chem2010; 285: 12490–12496.
47.
MoultonVRGrammatikosAPFitzgeraldLMTsokosGC. Splicing factor SF2/ASF rescues IL-2 production in T cells from systemic lupus erythematosus patients by activating IL-2 transcription. Proc Natl Acad Sci USA2013; 110: 1845–1850.
48.
RichardsonBScheinbartLStrahlerJGrossLHanashSJohnsonM. Evidence for impaired T cell DNA methylation in systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum1990; 33: 1665–1673.
49.
SunahoriKJuangYTTsokosGC. Methylation status of CpG islands flanking a cAMP response element motif on the protein phosphatase 2Ac alpha promoter determines CREB binding and activity. J Immunol2009; 182: 1500–1508.
50.
SunahoriKJuangYTKyttarisVCTsokosGC. Promoter hypomethylation results in increased expression of protein phosphatase 2A in T cells from patients with systemic lupus erythematosus. J Immunol2011; 186: 4508–4517.
51.
ZhouYQiuXLuoY. Histone modifications and methyl-CpG-binding domain protein levels at the TNFSF7 (CD70) promoter in SLE CD4+ T cells. Lupus2011; 20: 1365–1371.
52.
ZhaoMTangJGaoF. Hypomethylation of IL10 and IL13 promoters in CD4+ T cells of patients with systemic lupus erythematosus. J Biomed Biotechnol2010; 2010: 931018–931018.
53.
RauenTHedrichCMJuangYTTenbrockKTsokosGC. cAMP-responsive element modulator (CREM)alpha protein induces interleukin 17A expression and mediates epigenetic alterations at the interleukin-17A gene locus in patients with systemic lupus erythematosus. J Biol Chem2011; 286: 43437–43446.
54.
CoitPJeffriesMAltorokN. Genome-wide DNA methylation study suggests epigenetic accessibility and transcriptional poising of interferon-regulated genes in naïve CD4+ T cells from lupus patients. J Autoimmuni2013; 43: 78–84.
55.
AbsherDMLiXWaiteLL. Genome-wide DNA methylation analysis of systemic lupus erythematosus reveals persistent hypomethylation of interferon genes and compositional changes to CD4+ T-cell populations. PLoS Genet2013; 9: e1003678–e1003678.
56.
HuNQiuXLuoY. Abnormal histone modification patterns in lupus CD4+ T cells. J Rheumatol2008; 35: 804–810.
57.
HedrichCMRauenTTsokosGC. cAMP-responsive element modulator (CREM)alpha protein signaling mediates epigenetic remodeling of the human interleukin-2 gene: Implications in systemic lupus erythematosus. J Biol Chem2011; 286: 43429–43436.
58.
MishraNReillyCMBrownDRRuizPGilkesonGS. Histone deacetylase inhibitors modulate renal disease in the MRL-lpr/lpr mouse. J Clin Invest2003; 111: 539–552.
59.
ReillyCMMishraNMillerJM. Modulation of renal disease in MRL/lpr mice by suberoylanilide hydroxamic acid. J Immunol2004; 173: 4171–4178.
60.
TangYLuoXCuiH. MicroRNA-146A contributes to abnormal activation of the type I interferon pathway in human lupus by targeting the key signaling proteins. Arthritis Rheum2009; 60: 1065–1075.
61.
FanWLiangDTangY. Identification of microRNA-31 as a novel regulator contributing to impaired interleukin-2 production in T cells from patients with systemic lupus erythematosus. Arthritis Rheum2012; 64: 3715–3725.
62.
PanWZhuSYuanM. MicroRNA-21 and microRNA-148a contribute to DNA hypomethylation in lupus CD4+ T cells by directly and indirectly targeting DNA methyltransferase 1. J Immunol2010; 184: 6773–6781.
63.
GarchowBGBartulos EncinasOLeungYT. Silencing of microRNA-21 in vivo ameliorates autoimmune splenomegaly in lupus mice. EMBO Mol Med2011; 3: 605–615.
64.
StagakisEBertsiasGVerginisP. Identification of novel microRNA signatures linked to human lupus disease activity and pathogenesis: miR-21 regulates aberrant T cell responses through regulation of PDCD4 expression. Ann Rheum Dis2011; 70: 1496–1506.
65.
DavisTEKis-TothKTsokosGC. A114: Methylprednisolone-induced inhibition of miR-155 expression increases SOCS1-driven suppression of cytokine signaling. Arthritis Rheumatol2014; 66(Suppl 11): S151–S151.
66.
DavisTEKis-TothKSzantoATsokosGC. Glucocorticoids suppress T cell function by up-regulating microRNA-98. Arthritis Rheum2013; 65: 1882–1890.
67.
KornTBettelliEOukkaMKuchrooVK. IL-17 and Th17 cells. Annu Rev Immunol2009; 27: 485–517.
68.
MiossecPKornTKuchrooVK. Interleukin-17 and type 17 helper T cells. N Engl J Med2009; 361: 888–898.
69.
ApostolidisSACrispínJCTsokosGC. IL-17-producing T cells in lupus nephritis. Lupus2011; 20: 120–124.
70.
ChengFGuoZXuHYanDLiQ. Decreased plasma IL22 levels, but not increased IL17 and IL23 levels, correlate with disease activity in patients with systemic lupus erythematosus. Ann Rheum Dis2009; 68: 604–606.
71.
ChenXQYuYCDengHH. Plasma IL-17A is increased in new-onset SLE patients and associated with disease activity. J Clin Immunol2010; 30: 221–225.
72.
ZhaoXFPanHFYuanH. Increased serum interleukin 17 in patients with systemic lupus erythematosus. Mol Biol Rep2010; 37: 81–85.
73.
CrispínJCOukkaMBaylissG. Expanded double negative T cells in patients with systemic lupus erythematosus produce IL-17 and infiltrate the kidneys. J Immunol2008; 181: 8761–8766.
74.
VillanuevaEYalavarthiSBerthierCC. Netting neutrophils induce endothelial damage, infiltrate tissues, and expose immunostimulatory molecules in systemic lupus erythematosus. J Immunol2011; 187: 538–552.
75.
ZhangZKyttarisVCTsokosGC. The role of IL-23/IL-17 axis in lupus nephritis. J Immunol2009; 183: 3160–3169.
76.
WangYItoSChinoY. Laser microdissection-based analysis of cytokine balance in the kidneys of patients with lupus nephritis. Clin Exp Immunol2010; 159: 1–10.
77.
LeeYAwasthiAYosefN. Induction and molecular signature of pathogenic TH17 cells. Nat Immunol2012; 13: 991–999.
78.
GhoreschiKLaurenceAYangXP. Generation of pathogenic T(H)17 cells in the absence of TGF-beta signalling. Nature2010; 467: 967–971.
79.
ZielinskiCEMeleFAschenbrennerD. Pathogen-induced human TH17 cells produce IFN-gamma or IL-10 and are regulated by IL-1beta. Nature2012; 484: 514–518.
80.
RameshRKozhayaLMcKevittK. Pro-inflammatory human Th17 cells selectively express P-glycoprotein and are refractory to glucocorticoids. J Exp Med2014; 211: 89–104.
81.
IsgroJGuptaSJacekE. Enhanced rho-associated protein kinase activation in patients with systemic lupus erythematosus. Arthritis Rheum2013; 65: 1592–1602.
82.
KogaTHedrichCMMizuiM. CaMK4-dependent activation of AKT/mTOR and CREM-alpha underlies autoimmunity-associated Th17 imbalance. J Clin Invest2014; 124: 2234–2245.
83.
LeonardiCMathesonRZachariaeC. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med2012; 366: 1190–1199.
84.
BaetenDBaraliakosXBraunJ. Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: A randomised, double-blind, placebo-controlled trial. Lancet2013; 382: 1705–1713.
85.
McInnesIBSieperJBraunJ. Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: A 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial. Ann Rheum Dis2014; 73: 349–356.
86.
PappKALeonardiCMenterA. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med2012; 366: 1181–1189.
87.
WinchesterDDuffinKCHansenC. Response to ustekinumab in a patient with both severe psoriasis and hypertrophic cutaneous lupus. Lupus2012; 21: 1007–1010.
88.
DahlCJohansenCKragballeKOlesenAB. Ustekinumab in the treatment of refractory chronic cutaneous lupus erythematosus: A case report. Acta Derm Venereol2013; 93: 368–369.
89.
CrispínJCTsokosGC. Human TCR-alpha beta+ CD4– CD8– T cells can derive from CD8+ T cells and display an inflammatory effector phenotype. J Immunol2009; 183: 4675–4681.
90.
RajagopalanSZordanTTsokosGCDattaSK. Pathogenic anti-DNA autoantibody-inducing T helper cell lines from patients with active lupus nephritis: Isolation of CD4–8– T helper cell lines that express the gamma delta T-cell antigen receptor. Proc Natl Acad Sci USA1990; 87: 7020–7024.
91.
ShivakumarSTsokosGCDattaSK. T cell receptor alpha/beta expressing double-negative (CD4–/CD8–) and CD4+ T helper cells in humans augment the production of pathogenic anti-DNA autoantibodies associated with lupus nephritis. J Immunol1989; 143: 103–112.
92.
HedrichCMRauenTCrispínJC. cAMP-responsive element modulator alpha (CREMalpha) trans-represses the transmembrane glycoprotein CD8 and contributes to the generation of CD3+CD4-CD8- T cells in health and disease. J Biol Chem2013; 288: 31880–31887.
93.
HedrichCMCrispínJCRauenT. cAMP responsive element modulator (CREM) alpha mediates chromatin remodeling of CD8 during the generation of CD3+ CD4– CD8– T cells. J Biol Chem2014; 289: 2361–2370.
94.
CampbellDJKochMA. Phenotypical and functional specialization of FOXP3+ regulatory T cells. Nat Rev Immunol2011; 11: 119–130.
95.
CrispínJCMartínezAAlcocer-VarelaJ. Quantification of regulatory T cells in patients with systemic lupus erythematosus. J Autoimmun2003; 21: 273–276.
96.
ValenciaXYarboroCIlleiGLipskyPE. Deficient CD4+CD25high T regulatory cell function in patients with active systemic lupus erythematosus. J Immunol2007; 178: 2579–2588.
97.
BarathSAlekszaMTarrTSipkaSSzegediGKissE. Measurement of natural (CD4+CD25high) and inducible (CD4+IL-10+) regulatory T cells in patients with systemic lupus erythematosus. Lupus2007; 16: 489–496.
98.
VenigallaRKTretterTKrienkeS. Reduced CD4+,CD25– T cell sensitivity to the suppressive function of CD4+,CD25high,CD127–/low regulatory T cells in patients with active systemic lupus erythematosus. Arthritis Rheum2008; 58: 2120–2130.
99.
YatesJWhittingtonAMitchellPLechlerRILightstoneLLombardiG. Natural regulatory T cells: Number and function are normal in the majority of patients with lupus nephritis. Clin Exp Immunol2008; 153: 44–55.
100.
GoldingAHasniSIlleiGShevachEM. The percentage of FoxP3+Helios+ Treg cells correlates positively with disease activity in systemic lupus erythematosus. Arthritis Rheum2013; 65: 2898–2906.
101.
Vargas-RojasMICrispínJCRichaud-PatinYAlcocer-VarelaJ. Quantitative and qualitative normal regulatory T cells are not capable of inducing suppression in SLE patients due to T-cell resistance. Lupus2008; 17: 289–294.
102.
KogaTIchinoseKMizuiMCrispínJCTsokosGC. Calcium/calmodulin-dependent protein kinase IV suppresses IL-2 production and regulatory T cell activity in lupus. J Immunol2012; 189: 3490–3496.
103.
TangyeSGMaCSBrinkRDeenickEK. The good, the bad and the ugly—TFH cells in human health and disease. Nat Rev Immunol2013; 13: 412–426.
104.
ZhangXIngSFraserA. Follicular helper T cells: New insights into mechanisms of autoimmune diseases. Ochsner J2013; 13: 131–139.
105.
VinuesaCGCookMCAngelucciC. A RING-type ubiquitin ligase family member required to repress follicular helper T cells and autoimmunity. Nature2005; 435: 452–458.
106.
SchmittNUenoH. Blood Tfh cells come with colors. Immunity2013; 39: 629–630.
107.
FengXWangDChenJ. Inhibition of aberrant circulating Tfh cell proportions by corticosteroids in patients with systemic lupus erythematosus. PloS One2012; 7: e51982–e51982.
108.
SimpsonNGatenbyPAWilsonA. Expansion of circulating T cells resembling follicular helper T cells is a fixed phenotype that identifies a subset of severe systemic lupus erythematosus. Arthritis Rheum2010; 62: 234–244.
109.
TerrierBCostedoat-ChalumeauNGarridoM. Interleukin 21 correlates with T cell and B cell subset alterations in systemic lupus erythematosus. J Rheumatol2012; 39: 1819–1828.
110.
MerrillJTBurgos-VargasRWesthovensR. The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: Results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial. Arthritis Rheum2010; 62: 3077–3087.
111.
FurieRNichollsKChengTT. Efficacy and safety of abatacept in lupus nephritis: A twelve-month, randomized, double-blind study. Arthritis Rheum2014; 66: 379–389.
112.
Desai-MehtaALuLRamsey-GoldmanRDattaSK. Hyperexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production. J Clin Invest1996; 97: 2063–2073.
113.
BlossomSChuEBWeigleWOGilbertKM. CD40 ligand expressed on B cells in the BXSB mouse model of systemic lupus erythematosus. J Immunol1997; 159: 4580–4586.
114.
KoshyMBergerDCrowMK. Increased expression of CD40 ligand on systemic lupus erythematosus lymphocytes. J Clin Invest1996; 98: 826–837.
115.
EarlyGSZhaoWBurnsCM. Anti-CD40 ligand antibody treatment prevents the development of lupus-like nephritis in a subset of New Zealand black × New Zealand white mice. Response correlates with the absence of an anti-antibody response. J Immunol1996; 157: 3159–3164.
116.
RussellJQMooneyTCohenPLMacPhersonBNoelleRJBuddRC. Anti-CD40L accelerates renal disease and adenopathy in MRL-lpr mice in parallel with decreased thymocyte apoptosis. J Immunol1998; 161: 729–739.
117.
Kalunian KC, Davis JC Jr, Merrill JT, Totoritis MC, Wofsy D; IDEC-131 Lupus Study Group. Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: A randomized, double-blind, placebo-controlled trial. Arthritis Rheum2002; 46: 3251–3258.
118.
BoumpasDTFurieRManziS. A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum2003; 48: 719–727.
119.
HutloffABüchnerKReiterK. Involvement of inducible costimulator in the exaggerated memory B cell and plasma cell generation in systemic lupus erythematosus. Arthritis Rheum2004; 50: 3211–3220.
120.
YangJHZhangJCaiQ. Expression and function of inducible costimulator on peripheral blood T cells in patients with systemic lupus erythematosus. Rheumatology2005; 44: 1245–1254.
121.
IwaiHAbeMHiroseS. Involvement of inducible costimulator-B7 homologous protein costimulatory pathway in murine lupus nephritis. J Immunol2003; 171: 2848–2854.
